Advanced Hemostatic Agents in trauma care - A cross-sectional study
Abstract
Introduction: Traumatic injuries present a global public health challenge, emphasizing the importance of effective bleeding management to improve patient outcomes. Advanced hemostatic agents (AHAs) offer promising alternatives to traditional methods, yet comprehensive research on their utilization, efficacy, and safety in trauma care is lacking. This study aims to evaluate the landscape of AHAs in trauma care, assessing efficacy, safety, adoption trends, and clinical practices to inform evidence-based guidelines and optimize patient care. Materials and Methods: A cross-sectional study was conducted across multiple trauma centers, collecting data on patient demographics, injury characteristics, hemostatic agent usage, clinical outcomes, and hospital settings. Utilization rates, adoption trends, and safety outcomes were analyzed using descriptive statistics, time-series analysis, and regression modeling. Results: Demographic analysis of 500 trauma patients revealed a predominance of males (70%) and blunt trauma (80%), with motor vehicle accidents being the leading cause. AHAs were utilized in 60% of cases, achieving hemostasis in 85% within the first hour. Significant reductions in transfusion requirements were observed with AHA use. Adverse events were rare, with thromboembolic events occurring in 2% of cases. Multivariable regression identified trauma severity, mechanism of injury, and time to treatment initiation as predictors of AHA utilization, while trauma severity, age, and type of AHA were predictors of clinical outcomes. Conclusion: This study provides comprehensive insights into AHA utilization, efficacy, and safety in trauma care, informing evidence-based practice and guiding future research to optimize patient outcomes. The findings underscore the importance of tailored treatment strategies and standardized protocols in enhancing trauma care delivery.
Description
Traumatic injuries represent a significant public health concern worldwide, with substantial morbidity and mortality rates. Effective management of traumatic bleeding is paramount in preventing adverse outcomes and optimizing patient survival and recovery. Traditional hemostatic methods, such as direct pressure and surgical ligation, have been mainstays in trauma care; however, advancements in medical technology have led to the development of advanced hemostatic agents (AHAs). These agents, ranging from topical hemostatic dressings to hemostatic agents with procoagulant properties, offer promising alternatives or adjuncts to traditional methods by rapidly controlling bleeding and promoting hemostasis.[1] The adoption of advanced hemostatic agents in trauma care has been steadily increasing, driven by their potential to improve outcomes in hemorrhagic shock and trauma-induced coagulopathy. However, despite their growing utilization, there remains a paucity of comprehensive, cross-sectional research that systematically evaluates the landscape of advanced hemostatic agents in trauma care. Such a study is crucial to: Assess Efficacy and Safety: Evaluate the clinical effectiveness and safety profile of advanced hemostatic agents compared to traditional hemostatic methods, including their impact on hemorrhage control, transfusion requirements, and complication rates. Examine Adoption Trends: Identify patterns and trends in the adoption and utilization of advanced hemostatic agents across different healthcare settings, including variations in usage based on trauma severity, patient demographics, and institutional protocols. Explore Clinical Practices: Investigate current clinical practices regarding the selection, application, and monitoring of advanced hemostatic agents in trauma care, including factors influencing decision-making among healthcare providers.[2,3] Address Knowledge Gaps: Fill existing gaps in knowledge regarding the optimal use and integration of advanced hemostatic agents into trauma protocols, including their role in prehospital settings, emergency departments, and surgical interventions.[4] Inform Evidence-Based Practice: Provide valuable insights and evidence to inform evidence-based guidelines and recommendations for the use of advanced hemostatic agents in trauma care, ultimately improving patient outcomes and reducing the burden of traumatic injuries.[5] Overall, a cross-sectional study focusing on advanced hemostatic agents in trauma care is essential to comprehensively evaluate their current role, challenges, and potential benefits in the management of traumatic bleeding. By addressing these critical aspects, such a study can contribute to the advancement of trauma care protocols and enhance the standard of care for patients suffering from traumatic injuries.
Volume & Issue
Volume 11 Issue 4
Keywords
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
The articles in Journal of Cardiovascular Disease Research are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
|
![]() ![]() ![]() ![]() ![]() ![]() |
|
Copyright � 2022 Journal of Cardiovascular Disease Research All Rights Reserved. Subject to change without notice from or liability to Journal of Cardiovascular Disease Research.
For best results, please use Internet Explorer or Google Chrome POLICIES & JOURNAL LINKS
Author Login
Reviewer Login About Publisher Advertising Policy Author's Rights and Obligations Conflict of Interest Policy Copyright Information Digital Archiving & Preservation Policies Editorial Policies Peer Review Policy Editorial & Peer Review Process License Information Plagiarism Policy Privacy Policy Protection of Research Participants (Statement On Human And Animal Rights) Publication Ethics and Publication Malpractice Statement Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Terms of Use |
Contact InformationJournal of cardiovascular Disease Research,
|